Kronos Advanced Technologies Inc. (KNOS)

Orchard Therapeutics Income Statement

Financials in millions USD. Fiscal year is July - June.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Revenue	0.02	0.14	0.08	0.5	0.04
Revenue Growth (YoY)	-84.47%	63.77%	-83.52%	1122.23%	6590.75%
Cost of Revenue	0.02	0.01	0.05	0.28	0.01
Gross Profit	0	0.12	0.03	0.23	0.03
Selling, General & Admin	-0.06	0.51	0.38	2.16	0.17
Operating Expenses	0.03	0.56	0.38	2.17	0.28
Operating Income	-0.03	-0.44	-0.35	-1.94	-0.25
Interest Expense	-0.21	-0.02	-0.07	-0.92	-0.31
Other Non Operating Income (Expenses)	-	-	-0	1.4	0.07
EBT Excluding Unusual Items	-0.23	-0.46	-0.42	-1.47	-0.49
Gain (Loss) on Sale of Assets	-1.04	-	-	-	-
Pretax Income	-1.27	-0.46	-0.42	-1.47	-0.49
Net Income	-1.27	-0.46	-0.42	-1.47	-0.49
Net Income to Common	-1.27	-0.46	-0.42	-1.47	-0.49
Shares Outstanding (Basic)	668	659	659	659	489
Shares Outstanding (Diluted)	668	659	659	659	489
Shares Change (YoY)	1.29%	-	-	34.78%	0.31%
EPS (Basic)	-0.00	-0.00	-0.00	-0.00	-0.00
EPS (Diluted)	-0.00	-0.00	-0.01	-0.00	-0.00
Free Cash Flow	-1.49	-0	-0.26	-8.99	-0.13
Free Cash Flow Per Share	-0.00	-	-	-0.01	-
Gross Margin	18.22%	90.36%	38.72%	45.19%	83.61%
Operating Margin	-122.14%	-323.11%	-421.76%	-385.32%	-600.64%
Profit Margin	-6005.47%	-335.97%	-508.38%	-290.85%	-1197.24%
Free Cash Flow Margin	-7070.17%	-3.18%	-316.15%	-1784.11%	-320.11%
EBITDA	-0.01	-0.42	-0.33	-1.92	-0.23
EBITDA Margin	-47.50%	-	-	-	-
D&A For EBITDA	0.02	0.02	0.02	0.02	0.02
EBIT	-0.03	-0.44	-0.35	-1.94	-0.25
EBIT Margin	-122.14%	-	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.